
Please try another search
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Bruce L. Booth | 50 | 2016 | Independent Chairman of the Board |
Stefan Vitorovic | 39 | 2021 | Independent Director |
Alise S. Reicin | 64 | - | President, CEO, Secretary & Director |
Terrance G. McGuire | 69 | 2019 | Independent Chairman of the Board |
Praveen P. Tipirneni | 57 | 2020 | Independent Director |
Phillip B. Donenberg | 64 | 2024 | Independent Director |
Timothy A. Springer | 76 | 2019 | Co-Founder & Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review